Benefit-Risk SIG

The Benefit-Risk SIG was set up at the start of 2012 to help support those involved in this fast evolving area.

The main aims of the SIG are:

• To understand how best to apply Benefit-Risk methodologies across the Pharmaceutical Industry
• To discuss and make recommendations on key methodological issues
• To share examples of how Benefit-Risk has been used within pharmaceutical companies
• To share external information including new developments around Benefit-Risk

Currently the SIG has subgroups working on:

• Literature review
• Benefit-Risk in the HTA setting (together with the HTA SIG)
• Bayesian applications in Benefit-Risk
• Preference elicitation and Benefit-Risk

We also develop relevant training in the area of structured Benefit-Risk as needed.

If you have an interest in being involved in this SIG, or have an interesting case study or experience of carrying out a structured Benefit-Risk assessment to share, please contact Maria Costa (email: maria_j.costa@novartis.com)

Our BLOG can be found under www.benefit-risk-assessment.com. It is a great source of information for all things Benefit-Risk related: upcoming conferences, journal publications, training, and much more.

Latest News

PSI Strategy and Increasing Membership

We held our PSI Strategy Meeting on 31st October. We had 30 attendees at the meeting and there was some excellent discussion.
more»
PSI Awards, VoD Launch, Conference, Elections and SIGs (Autumn Update)

I have really enjoyed my first year as Chair (one more to go). The last few months in particular have been very eventful.
more»

Show all news

Future Events

PSI Toxicology SIG Workshop 2019 - Dates: 02 – 03 Apr, 2019

This 1.5-day workshop will involve approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types.

(?)
PSI Journal Club: Missing Data - Dates: 24 – 24 Jan, 2019

Our next journal club, held jointly with the DIA, features two papers on the topic of Statistical Considerations for Innovative Designs in Clinical Trials. Please join us to hear Jason Yuan and Xiangmin Zhang present their recent work.

(?)